Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, using biochemical and immunohistochemistry analyses we report that a 50% global reduction of BIN1 protein levels resulting from a single <i>Bin1</i> allele deletion in mice does not change BACE1 levels or localization <i>in vivo</i>, nor does this reduction alter the production of endogenous murine Aβ in nontransgenic mice.
|
30692199 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These plant metabolites have been shown to ameliorate AD by increasing the expression of insulin degrading enzyme (IDE), neprilysin (NEP), PPAR-γ, and α-secretase, and decreasing the expression of β-secretase (BACE-1) to reduce the levels of Aβ oligomers (Aβ<sub>O</sub>) deposition in brain neurons.
|
30877973 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The identified aptamers interacted with BACE1 in pull-down assay, inhibited BACE1 activity in in vitro fluorescence resonance energy transfer (FRET) assay and HEK293-APP stable cell line, reduced Aβ in the culture medium of HEK293-amyloid protein precursor (APP) stable cell line and APP-PS1 primary cultured neurons, and rescued Aβ-induced neuronal deficiency in APP-PS1 primary cultured neurons.
|
30959405 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid precursor protein (APP) is processed along the amyloidogenic pathway by the β-secretase, BACE1, generating β-amyloid (Aβ), or along the nonamyloidogenic pathway by α-secretase, precluding Aβ production.
|
30545942 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aβ deposition in turn causes accumulation of BACE1 in plaque-associated dystrophic neurites, thereby potentiating progressive Aβ deposition once initiated.
|
31701556 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Secretase (BACE1) and acetylcholinesterase (AChE), which are required for the production of neurotoxic β-amyloid (Aβ) and the promotion of Aβ fibril formation, respectively, are considered as prime therapeutic targets for AD.
|
30717208 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we conclude that Syn1 may promote Aβ production via the modulation of BACE1.
|
31830091 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A combination of compound 2a with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds.
|
30873837 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the levels of amyloid-β protein (Aβ), phosphorylated-tau (Ser396), malondialdehyde (MDA), interleukin 1-beta (IL-1β), tumor necrosis alpha (TNFα), p- Glycogen synthase kinase-3β (p-GSK3β) (Tyr216), and β-secretase (BACE1) gene expression were increased in socially isolated aluminum treated rats, yet, vinpocetine treatment reversed these deteriorating effects.
|
31175888 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of β-amyloid (Aβ) peptides and is considered a potential treatment target for Alzheimer's disease (AD).
|
30347431 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study confirmed this hypothesis by showing that PPARγ agonist pioglitazone attenuated the neuronal apoptosis of primary rat hippocampal neurons induced by Aβ<sub>1-42</sub>, downregulated CDK5 expression, weakened the binding of CDK5 to PPARγ, reduced PPARγ phosphorylation, increased the expression of PPARγ and IDE, decreased the expression of BACE1, reduced APP production, and downregulated intraneuronal Aβ<sub>1-42</sub> levels.
|
31379559 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-200a-3p Mediates Neuroprotection in Alzheimer-Related Deficits and Attenuates Amyloid-Beta Overproduction and Tau Hyperphosphorylation <i>via</i> Coregulating BACE1 and PRKACB.
|
31379578 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transplantation of BDNF modified hUC-MSCs-derived cholinergic-like neurons significantly improved spatial learning and memory abilities in the AD rats, increased the release of acetylcholine and ChAT expression in the hippocampus, enhanced the activation of astrocytes and microglia, reduced the expression of Aβ and recombinant human beta-site APP-cleaving enzyme1 (BACE1), inhibited neuronal apoptosis, and promoted neurogenesis.
|
30586546 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) to prevent brain β-amyloid (Aβ) peptide's formation is a potential effective approach to treat Alzheimer's disease.
|
31711785 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This age-dependent shift in Aβ peptide profile coincided with reduced expression of glycosylated species of ADAM-10 (α-secretase) and BACE1 (β-secretase), and an increased co-immunoprecipitation of presenilin-1 with nicastrin (components of the γ-secretase complex).
|
30803762 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ).
|
30970186 |
2019 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proteolytic enzyme β-secretase (BACE1) plays a central role in the synthesis of the pathogenic β-amyloid peptides (Aβ) in Alzheimer's disease (AD), antioxidants could attenuate the AD syndrome and prevent the disease progression.
|
31397505 |
2019 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
With regard to a potential mechanism, in both models, we found that the stroke-induced Aβ and tau deposits co-localized with increased levels of β-secretase 1 (BACE1), along with its substrate, neuregulin 1 (NGR1) type III, both of which are proteins integral for myelin repair.
|
30249297 |
2018 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-16 overexpression and BACE1 knockdown facilitated Aβ-induced cell toxicity, apoptosis, and caspase-3 activity in N2a cells, which was partially eliminated by overexpression of BACE1.
|
30142113 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE1 inhibition in mice with lower amyloidosis at treatment initiation showed a higher efficacy in attenuating progression to PET.
|
30429879 |
2018 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Focusing on the donor's sex and APOE ε4 status as nominal variables (i.e., omitting diagnosis from the stratification) revealed that increases in Aβ peptides were specific to female carriers of the ε4 allele and correlated with the proportional expression of BACE1/β-secretase and ADAM10/α-secretase in the cortex and with nicastrin (γ-secretase) expression in the hippocampus.
|
29331531 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ) clearance.
|
30519627 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protease Bace1 drives beta amyloid (Aβ) production with obesity elevating hypothalamic Bace1 activity and Aβ<sub>1-42</sub> production.
|
29311632 |
2018 |
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
BACE1 is the rate-limiting protease in the production of synaptotoxic β-amyloid (Aβ) species and hence one of the prime drug targets for potential therapy of Alzheimer's disease (AD).
|
29327084 |
2018 |
Amyloidosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The naringenin loaded nanoemulsion significantly alleviated the direct neurotoxic effects of Aβ on SH-SY5Y cells; this was associated with a down-regulation of APP and BACE expression, indicating reduced amyloidogenesis.
|
30001606 |
2018 |